A clinical risk score to predict 3-, 5- and 10-year survival in patients undergoing surgery for Dukes B colorectal cancer.
BACKGROUND
The prognosis of patients with Dukes stage B colorectal cancer is unpredictable and there is continuing interest in simply and reliably identifying patients at high risk of developing recurrence and dying of their disease. The aim of this study was to devise a clinical risk score to predict 3-, 5- and 10-year survival in patients undergoing surgery for Dukes stage B colorectal cancer.


METHODS
A total of 1350 patients who underwent surgery for Dukes stage B colorectal cancer between 1991 and 1994 in 11 hospitals in Scotland were included in the analysis.


RESULTS
On follow-up, 926 patients died of whom 479 died of their cancer. At 10 years, cancer-specific survival was 61% and overall survival was 38%. On multivariate analysis, age ≥75 (hazard ratio (HR) 1.45, 95% confidence interval (CI) 1.15-1.82, P=0.001), emergency presentation (HR 1.59, 95% CI 1.27-1.99, P<0.001) and anastomotic leak (HR 2.17, 95% CI 1.24-3.78, P<0.01) were independently associated with cancer-specific survival in colon cancer. On multivariate analysis, only age ≥75 (HR 1.58, 95% CI 1.14-2.18, P<0.01) was associated with cancer-specific survival in rectal cancer. Age, presentation and anastomotic leak hazards could be simply added to form a clinical risk score from 0 to 2 in colon cancer. In patients with Dukes B stage colon cancer, the cancer-specific survival at 5 years for patients with a cumulative score 0 was 81%, 1 was 67% and 2 was 63%. The cancer-specific survival rate at 10 years for patients with a clinical risk score of 0 was 72%, 1 was 58% and 2 was 53%.


CONCLUSIONS
The results of this study, in a mature cohort, introduce a new simple clinical risk score for patients undergoing surgery for Dukes B colon cancer. This provides a solid foundation for the examination of the impact of additional factors and treatment on prediction of 3-, 5- and 10-year cancer-specific survival.
McMillan
D C
DC
University Department of Surgery, Faculty of Medicine, University of Glasgow, Royal Infirmary, Glasgow G31 2ER, UK. d.c.mcmillan@clinmed.gla.ac.uk
McArdle
C S
CS
Morrison
D S
DS
D000367:Age Factors; D000368:Aged; D000714:Anastomosis, Surgical / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D011379:Prognosis; D012307:Risk Factors; D015996:Survival Rate
Semin Oncol. 2010 Feb;37(1):39-46
20172363
Br J Surg. 2006 Apr;93(4):483-8
16555262
Surgery. 2006 Mar;139(3):296-304
16546492
J Clin Oncol. 2004 Aug 15;22(16):3408-19
15199089
Br J Surg. 2002 May;89(5):586-90
11972548
Dis Colon Rectum. 2008 Feb;51(2):223-30
18097722
Br J Cancer. 2006 Oct 23;95(8):979-85
17047646
Ann Oncol. 2003;14 Suppl 2:ii25-9
12810454
Ann Surg Oncol. 2007 Sep;14(9):2559-66
17522945
Dis Colon Rectum. 2009 Dec;52(12):1982-91
19959975
Br Med Bull. 2002;64:119-25
12421729
Br J Surg. 2005 Sep;92(9):1150-4
16035134
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s
18006800
Br J Surg. 1994 May;81(5):736-8
8044567
Future Oncol. 2010 Jan;6(1):149-63
20021215
Br J Surg. 2004 May;91(5):610-7
15122614
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
19318937
Br J Surg. 2007 Dec;94(12):1548-54
17668888
Br J Surg. 2003 Jun;90(6):711-5
12808619
Colorectal Dis. 2010 Oct;12(10):987-94
19555389
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Br J Surg. 2004 May;91(5):605-9
15122613
Eur J Surg Oncol. 1998 Oct;24(5):391-5
9800966
Br J Cancer. 2008 Oct 7;99(7):1046-9
18797465
Soc Sci Med. 2009 Jan;68(2):290-7
19022550
Br J Surg. 2010 Jul;97(7):1035-42
20632269